Pharnext to Present at Rodman & Renshaw 19th Annual Global Investment Conference
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference.
The presentation will take place as follows:
- Date: Tuesday, September 12th, 2017
- Time: 5:30 pm EDT (11:30 pm CEST)
- Venue: Lotte New York Palace Hotel in New York, New York
If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at matthew@sternir.com.
About Pharnext
Pharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the treatment
of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug
status in Europe and the United States. PXT864 has generated positive
Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new
drug discovery paradigm: PLEOTHERAPY™. The Company identifies and
develops synergic combinations of repositioned drugs at new optimal
lower doses. These PLEODRUG™ offer several key advantages: efficacy,
safety and intellectual property including several product or
composition of matter patents already granted. The Company is supported
by a world-class scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange in
Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005711/en/
Contact information
Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
Chief
Commercial Officer
contact@pharnext.com
or
Investor
Relations (Europe)
MC Services AG
Anne Hennecke, +49 211
529252 22
anne.hennecke@mc-services.eu
or
Media
Relations (Europe)
ALIZE RP
Caroline Carmagnol
Margaux
Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Investor
Relations (U.S.)
Stern Investor Relations, Inc.
Matthew
Shinseki, +1 212-362-1200
matthew@sternir.com
or
Media
Relations (U.S.)
Russo Partners
Tony Russo
Scott
Santiamo
tony.russo@russopartnersllc.com
scott.santiamo@russopartnersllc.com
+1
212-845-4251
+1 718-344-5843
or
Financial
Communication (France)
New CAP
Emmanuel Huynh, +33 (0)1 44
71 20 40
pharnext@newcap.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Expanded Indication for VONVENDI ® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease6.9.2025 03:45:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von Willebrand Disease (VWD), including those with Type 1 and 2 disease, and on-demand and perioperative management of bleeding in pediatric patients with VWD. VONVENDI was previously approved for on-demand and perioperative use in adults with VWD and routine prophylactic use in adults with severe Type 3 VWD receiving on-demand therapy.1 VONVENDI is now available for use in a broad range of VWD patients and is the only recombinant von Willebrand Factor (VWF) replacement therapy with approved indications in both adults and children with VWD.1 VWD is the most common bleeding disorder impacting more than 3 million people in the U.S. alone. It occurs equally among men
Samsung Unveils “AI Home: Future Living, Now” Vision at IFA 20256.9.2025 00:34:00 EEST | Press release
At Innovation For All (IFA) 2025, Samsung Electronics showcased its vision for “AI Home: Future Living, Now”. Samsung’s AI Home aims to be a reality people can experience today — not just in the future — and one designed for everyone, not just a select few. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905654772/en/ Cheolgi Kim, Head of Digital Appliances, presents Future Living Now at Samsung’s IFA 2025 press conference in Berlin “At Samsung, we’re not just imagining the future of AI; we’re building it into everyday life. Samsung’s AI Home moves beyond smart devices to homes that truly understand you, adapt to your needs, and care for what matters most,” said Cheolgi Kim (CK), Executive Vice President and Head of Digital Appliances (DA) Business. “This is the beginning of a new era - where technology supports your life in the background so that you can live it more fully.” Samsung’s AI Home experience is designed to mak
NetApp named a Leader by Gartner® in the 2025 Magic Quadrant™ for Enterprise Storage Platforms5.9.2025 18:15:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2025 Gartner Magic Quadrant for Enterprise Storage Platforms. NetApp believes this recognition reflects how the company’s continuous innovation helps customers build Intelligent Data Infrastructure to face modern technology challenges, including protection from cyber threats and using AI to drive data-based decisions. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. According to Gartner, “Enterprise storage platforms offer platform-native service capabilities and product features for both structured and unstructured data workloads. Heads of infrastructure and operations should use this research to assess vendors in deploying a modern IT infrastructure platform for block, file and object storage.” This report combines the previous Gartner Magic Quadrant reports for the Pri
Capcom’s Popular Title Street Fighter’s Live-Action Movie Starts Filming!5.9.2025 16:00:00 EEST | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that filming has commenced on a live-action film adaptation of its popular fighting game series Street Fighter, in collaboration with Legendary Entertainment (Legendary), with both companies jointly financing the project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250905806122/en/ Street Fighter Movie Title Logo To expand global sales of its core home video game software business, Capcom is actively promoting the branding of its proprietary IP under the Single Content Multiple Usage strategy. Particularly, the adaptation of game content into visual media is a valuable opportunity to broaden awareness of Capcom’s IP beyond the gaming audience. With filming of the upcoming film Street Fighter now starting, the casting of the main characters—Ken, Ryu, and Chun-Li —has been finalized. Through joint financing with Legendary, a company renowned for producing numerous blockbuster fi
Motive’s Entitlement Server Acknowledged as a Pacesetter in Counterpoint Research’s 2025 Rankings5.9.2025 16:00:00 EEST | Press release
Motive, a global leader in device management, today announced its recognition as a Pacesetter in Counterpoint Research’s 2025 Entitlement Server Rankings. Counterpoint placed Motive in its highest top-right Pacesetter quadrant: the most advanced recognition in the ranking. This accolade reflects Motive’s decisive investment in entitlement orchestration at a time when operators face urgent deadlines, including Apple’s September 2025 RCS requirement. Motive has taken the lead, proving ability to deliver at scale, currently deployed in large mobile service providers across North America, Europe, Africa, the Middle East, Asia-Pacific, and Latin America. Removing Barriers to RCS and Beyond The industry has long wrestled with the lack of a commercial framework for Rich Business Messaging (RBM) and lack of cross platform support between Android and iOS. Motive addresses this by ensuring operators can enable RCS on both Apple and Android devices securely without delay. This approach derisks op
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom